Clinical perspective on PROSE: does VeriStrat testing improve selection of second-line treatment for patients with non-small cell lung cancer?

Lignende værker

• Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients
  af: Jia, Bo, et al.
  Udgivet: (2020)
• The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients
  af: Fidler, Mary Jo, et al.
  Udgivet: (2018)
• The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy()
  af: Lee, Siow Ming, et al.
  Udgivet: (2019)
• VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib
  af: Kuiper, J L, et al.
  Udgivet: (2012)
• Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer
  af: Landi, Lorenza, et al.
  Udgivet: (2015)